End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B

AIM: Attaining hepatitis B e antigen (HBeAg) seroconversion during lamivudine treatment is associated with fewer relapses in HBeAg-positive patients. In HBeAg-negative patients, predictors for post-treatment relapse remain largely unknown. We therefore studied whether end-of-treatment virologic resp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:World J Gastroenterol
Päätekijät: Liu, Chun-Jen, Huang, Wen-Ling, Chen, Pei-Jer, Lai, Ming-Yang, Kao, Jia-Horng, Chen, Ding-Shinn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Baishideng Publishing Group Inc 2004
Aiheet:
Viral Hepatitis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4611995/
https://ncbi.nlm.nih.gov/pubmed/15534909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v10.i24.3574
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia